Barclays raised the firm’s price target on Repligen (RGEN) to $200 from $175 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the “most under-owned space in healthcare” creates a “great setup” for outperformance of the tools group in 2026, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen’s Q3 Earnings Call: Strong Growth and Positive Outlook
- Repligen price target raised to $165 from $150 at Canaccord
- Repligen price target raised to $175 from $160 at Barclays
- Repligen Corporation Reports Strong Q3 2025 Results
- Repligen’s Strong Performance and Strategic Growth Initiatives Earn ‘Buy’ Rating